Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | MPI | P34949 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.52 |
| ▸ | METAP1 | P53582 | 1/20 | 0.52 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.52 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540649 | 0.84 | HTR1A (0.56) | HTTSLC6A2KMT2AMEN1MAPT | |
| Tiliquinol SCHEMBL30831638 | 0.84 | HTT (1.00) | HTTSLC6A2KMT2AMEN1MAPT | |
| Tiliquinol SCHEMBL145245 | 0.84 | HTT (1.00) | HTTSLC6A2KMT2AMEN1MAPT | |
| SCHEMBL812451 | 0.83 | HTT (0.70) | HTTSLC6A2KMT2AMEN1MAPT | |
| SCHEMBL1920452 | 0.83 | KDM4E (0.70) | HTTSLC6A2KMT2AMEN1MAPT | |
| Tiliquinol SCHEMBL2876839 | 0.82 | HTT (0.96) | HTTSLC6A2KMT2AMEN1MAPT | |
| Tiliquinol SCHEMBL28651750 | 0.82 | HTT (0.96) | HTTSLC6A2KMT2AMEN1MAPT | |
| Tiliquinol SCHEMBL4776013 | 0.82 | HTT (0.96) | HTTSLC6A2KMT2AMEN1MAPT | |
| Tiliquinol SCHEMBL175614 | 0.82 | HTT (0.96) | HTTSLC6A2KMT2AMEN1MAPT | |
| Tiliquinol SCHEMBL27600011 | 0.82 | HTT (0.96) | HTTSLC6A2KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236792-A1 | ETCHANT COMPOSITION FOR ETCHING SILICON AND METHOD OF FORMING PATTERN USING THE SAME | DONGWOO FINE-CHEM CO., LTD. (KR) | 2025-07-24 | — | — | US | disclosed |
| CN-117986220-A | Method for preparing substituted chromanone derivative | 杭州杜易科技有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-114222734-B | Method for preparing substituted chromanone derivative | 杭州杜易科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-114222734-A | Method for preparing substituted chromanone derivative | 杭州杜易科技有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7960155-B1 | Cytochrome p450 monooxygenases and their use for oxidizing organic compounds | BASF AKTIENGESELLSCHAFT (DE) | 2011-06-14 | — | — | US | disclosed |
| EP-1196605-B1 | NOVEL CYTOCHROME P450 MONOOXYGENASES AND THEIR USE FOR OXIDIZING ORGANIC COMPOUNDS | BASF SE (DE) | 2008-09-24 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1196605-A1 | NOVEL CYTOCHROME P450 MONOOXYGENASES AND THEIR USE FOR OXIDIZING ORGANIC COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001007630-A1 | NOVEL CYTOCHROME P450 MONOOXYGENASES AND THEIR USE FOR OXIDIZING ORGANIC COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2001-02-01 | — | — | WO | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
| EP-0132714-B1 | PROCESS FOR THE PREPARATION OF QUINOLINES | BASF Aktiengesellschaft (DE) | 1987-01-28 | — | — | EP | disclosed |
| US-3956420-A | CPOLYOLEFIN COMPOSITION FOR ELECTRICAL INSULATIONFERROCENE, 8-SUBSTITUTED QUINOLINE | DAINICHI-NIPPON CABLES, LTD. (JA) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HTT 4644/4885SLC6A2 3396/4885KMT2A 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.